The impact of vaccination and outpatient treatment on the economic burden of Covid-19 in the United States omicron era: a systematic literature review

References

• Centers for Disease Control and Prevention. COVID Data Tracker 2023; [cited 2023 Aug 9]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home.
   Google Scholar
• Ahmad FB, Cisewski JA, Xu J, et al. Provisional mortality data – United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(18):488–492. doi:10.15585/mmwr.mm7218a3.
   PubMedGoogle Scholar
• Our World in Data. Coronavirus (COVID-19) Hospitalizations 2023; [cited 2023 Aug 14]. Available from: https://ourworldindata.org/covid-hospitalizations.
   Google Scholar
• Glaser GE, Lara OD, Pothuri B, et al. Clinical outcomes in patients with COVID-19 and gynecologic cancer: a society of gynecologic oncology COVID-19 and gynecologic cancer registry study. Gynecol Oncol. 2022;166:s34. doi:10.1016/j.ygyno.2022.09.017.
   Google Scholar
• Di Fusco M, Vaghela S, Moran MM, et al. COVID-19-associated hospitalizations among children less than 12 years of age in the United States. J Med Econ. 2022;25(1):334–346. doi:10.1080/13696998.2022.2046401.
   PubMed Web of Science ®Google Scholar
• Tsai Y, Vogt TM, Zhou F. Patient characteristics and costs associated with COVID-19-related medical care among medicare fee-for-Service beneficiaries. Ann Intern Med. 2021;174(8):1101–1109. www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-1102.eng. doi:10.7326/m21-1102.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Long COVID - Household Pulse Survey. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. 2023.
   Google Scholar
• Perlis RH, Lunz Trujillo K, Safarpour A, et al. Association of Post-COVID-19 condition symptoms and employment status. JAMA Netw Open. 2023;6(2):e2256152. doi:10.1001/jamanetworkopen.2022.56152.
   PubMed Web of Science ®Google Scholar
• Hernandez-Romieu AC, Leung S, Mbanya A, et al. Health care utilization and clinical characteristics of nonhospitalized adults in an integrated health care system 28-180 days after COVID-19 Diagnosis – Georgia, may 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(17):644–650. doi:10.15585/mmwr.mm7017e3.
   PubMed Web of Science ®Google Scholar
• Bach K. New data shows long Covid is keeping as many as 4 million people out of work. https://www.brookings.edu/research/new-data-shows-long-covid-is-keeping-as-many-as-4-million-people-out-of-work/. 2022.
   Google Scholar
• World Health Organization. Fourth round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic: November 2022–January 2023. 2023.
   Google Scholar
• Taylor CA, Whitaker M, Anglin O, et al. COVID-19-Associated hospitalizations among adults during SARS-CoV-2 Delta and omicron variant predominance, by race/ethnicity and vaccination Status - COVID-NET, 14 states, July 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):466–473. doi:10.15585/mmwr.mm7112e2.
   PubMed Web of Science ®Google Scholar
• Admon AJ, Iwashyna TJ, Kamphuis LA, et al. Assessment of symptom, disability, and financial trajectories in patients hospitalized for COVID-19 at 6 months. JAMA Netw Open. 2023;6(2):e2255795. doi:10.1001/jamanetworkopen.2022.55795.
   PubMed Web of Science ®Google Scholar
• Gibbons DC, Marijam A, Symons JM, et al. Healthcare resource utilization and costs associated with COVID-19 among hospitalized patients in the United States – a population study. San Francisco: American Thoracic Society; 2022.
   Google Scholar
• Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html. 2021.
   Google Scholar
• Centers for Disease Control and Prevention. COVID data tracker. 2023.
   Google Scholar
• World Health Organization. Statement on omicron sublineage BA.2. 2022.
   Google Scholar
• US Department of Health and Human Services. Fact sheet: end of the COVID-19 public health emergency. 2023.
   Google Scholar
• World Health Organization. From emergency response to long-term COVID-19 disease management: sustaining gains made during the COVID-19 pandemic. 2023.
   Google Scholar
• Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. New York: CRD, University of York; 2009.
   Google Scholar
• Skarbinski J, Wood MS, Chervo TC, et al. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: a retrospective cohort study. Lancet Reg Health Am. 2022;12:100297. doi:10.1016/j.lana.2022.100297.
   PubMedGoogle Scholar
• Greene SK, Levin-Rector A, Kyaw NTT, et al. Comparative hospitalization risk for SARS-CoV-2 Omicron and Delta variant infections, by variant predominance periods and patient-level sequencing results, New York City, August 2021–January 2022. Influenza Other Respir Viruses. 2023;17(1):e13062. doi:10.1111/irv.13062.
   PubMed Web of Science ®Google Scholar
• Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, Delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. Bmj. 2022;376:e069761. doi:10.1136/bmj-2021-069761.
   PubMedGoogle Scholar
• Havers FP, Pham H, Taylor CA, et al. COVID-19-Associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, January 2021 to April 2022. JAMA Intern Med. 2022;182(10):1071–1081. doi:10.1001/jamainternmed.2022.4299.
   PubMed Web of Science ®Google Scholar
• Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-Associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 Years – VISION network, 10 States, April 2021–January 2022 [technical report]. MMWR Morb Mortal Wkly Rep. 2022;71(9):352–358. doi:10.15585/mmwr.mm7109e3.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Frankland TB, Slezak JM, et al. Effectiveness associated with BNT162b2 vaccine against emergency department and urgent care encounters for Delta and omicron SARS-CoV-2 infection among adolescents aged 12 to 17 years [research support, Non-U.S. Gov’t]. JAMA Netw Open. 2022;5(8):e2225162. doi:10.1001/jamanetworkopen.2022.25162.
   PubMed Web of Science ®Google Scholar
• Butt AA, Talisa VB, Shaikh OS, et al. Relative vaccine effectiveness of a SARS-CoV-2 mRNA vaccine booster dose against the omicron variant. Clin Infect Dis. 2022;3:03. doi:10.1093/cid/ciac328.
   Google Scholar
• Mehta HB, Li S, Goodwin JS. Effectiveness of COVID-19 booster on the risk of hospitalization among medicare beneficiaries. Mayo Clin Proc. 2022;97(10):1780–1793. doi:10.1016/j.mayocp.2022.06.029.
   PubMed Web of Science ®Google Scholar
• Kompaniyets L, Wiegand RE, Oyalowo AC, et al. Relative effectiveness of COVID-19 vaccination and booster dose combinations among 18.9 million vaccinated adults during the early SARS-CoV-2 omicron period – United States, 1 January 2022–31 March 2022. Clin Infect Dis. 2023;08:08. doi:10.1093/cid/ciad063.
   Google Scholar
• Bruxvoort KJ, Sy LS, Qian L, et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: interim results from a prospective observational cohort study. Lancet Reg Health Am. 2022;6:100134. doi:10.1016/j.lana.2021.100134.
   PubMedGoogle Scholar
• Anzalone AJ, Sun J, Vinson AJ, et al. Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: a retrospective cohort study from the national COVID cohort collaborative]. PLoS One. 2023;18(1):e0279968. doi:10.1371/journal.pone.0279968.
   PubMed Web of Science ®Google Scholar
• Risk M, Shen C, Hayek SS, et al. Comparative effectiveness of coronavirus disease 2019 (COVID-19) vaccines against the Delta variant [comparative study]. Clin Infect Dis. 2022;75(1):e623–e629. doi:10.1093/cid/ciac106.
   PubMedGoogle Scholar
• Tang F, Hammel IS, Andrew MK, et al. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 Delta (B.1.617.2) variant surge in the USA: a retrospective cohort study. Lancet Healthy Longev. 2022;3(9):e589–e598. doi:10.1016/S2666-7568(22)00166-0.
   PubMedGoogle Scholar
• Lin DY, Gu Y, Xu Y, et al. Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. Jama. 2022;328(14):1415–1426. doi:10.1001/jama.2022.17876.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. Lancet Reg Health Am. 2022;9:100198. doi:10.1016/j.lana.2022.100198.
   PubMedGoogle Scholar
• Winkelman TNA, Rai NK, Bodurtha PJ, et al. Trends in COVID-19 vaccine administration and effectiveness through october 2021 [research support, Non-U.S. JAMA Netw Open. 2022;5(3):e225018. doi:10.1001/jamanetworkopen.2022.5018.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States. Clin Infect Dis. 2022;74(9):1515–1524. doi:10.1093/cid/ciab687.
   PubMed Web of Science ®Google Scholar
• Florea A, Sy LS, Luo Y, et al. Durability of mRNA-1273 against COVID-19 in the time of Delta: interim results from an observational cohort study. PLoS One. 2022;17(4):e0267824. doi:10.1371/journal.pone.0267824.
   PubMed Web of Science ®Google Scholar
• Somani ST, Firestone RL, Donnelley MA, et al. Impact of vaccination on cost and course of hospitalization associated with COVID-19 infection. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e19. doi:10.1017/ash.2022.364.
   PubMedGoogle Scholar
• Olson SM, Newhams MM, Halasa NB, et al. Effectiveness of BNT162b2 vaccine against critical covid-19 in adolescents. N Engl J Med. 2022;386(8):713–723. doi:10.1056/NEJMoa2117995.
   PubMed Web of Science ®Google Scholar
• Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 Years - PROTECT cohort, July 2021–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(11):422–428. doi:10.15585/mmwr.mm7111e1.
   PubMed Web of Science ®Google Scholar
• Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84. doi:10.7326/M22-2141.
   PubMed Web of Science ®Google Scholar
• Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 – United States, April–September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531–1537. doi:10.15585/mmwr.mm7148e2.
   PubMed Web of Science ®Google Scholar
• Piccicacco N, Zeitler K, Ing A, et al. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the omicron surge. J Antimicrob Chemother. 2022;77(10):2693–2700. doi:10.1093/jac/dkac256.
   PubMed Web of Science ®Google Scholar
• Cheng MM, Reyes C, Satram S, et al. Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA. Infect Dis Ther. 2023;12(2):607–621. doi:10.1007/s40121-022-00755-0.
   PubMed Web of Science ®Google Scholar
• Gentry CA, Nguyen P, Thind SK, et al. Characteristics and outcomes of US veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Infect. 2023;86(3):248–255. doi:10.1016/j.jinf.2023.01.018.
   PubMed Web of Science ®Google Scholar
• Al-Obaidi MM, Gungor AB, Murugapandian S, et al. The impact of Nirmatrelvir-Ritonavir in reducing hospitalizations among high-risk patients with SARS-CoV-2 during the omicron predominant era. Am J Med. 2023;136(6):577–584. doi:10.1016/j.amjmed.2023.02.022.
   PubMed Web of Science ®Google Scholar
• Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infectious Diseases. 2023;10:10. doi:10.1016/S1473-3099(23)00011-7.
   Google Scholar
• Sridhara S, Gungor AB, Erol HK, et al. Lack of effectiveness of bebtelovimab monoclonal antibody among high-risk patients with SARS-Cov-2 Omicron during BA.2, BA.2.12.1 and BA.5 subvariants dominated era [preprint]. medRxiv. 2022;07.doi:https://doi.org/10.1101/2022.12.06.22283183.
   Google Scholar
• Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: information for Healthcare Professionals. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. 2023.
   Google Scholar
• Bajema KL, Wang XQ, Hynes DM, et al. Early adoption of anti-SARS-CoV-2 pharmacotherapies among US veterans with mild to moderate COVID-19, January and February 2022. JAMA Netw Open. 2022;5(11):e2241434. doi:10.1001/jamanetworkopen.2022.41434.
   PubMed Web of Science ®Google Scholar
• Danza P, Koo TH, Haddix M, et al. SARS-CoV-2 infection and hospitalization among adults aged > =18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (omicron) Variant Predominance – Los angeles county, California, 7 November 2021–8 January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5):177–181. doi:10.15585/mmwr.mm7105e1.
   PubMed Web of Science ®Google Scholar
• Paredes MI, Lunn SM, Famulare M, et al. Associations between severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) variants and risk of coronavirus disease 2019 (COVID-19) hospitalization among confirmed cases in Washington State: a retrospective cohort study. Clin Infect Dis. 2022;75(1):e536–e544. doi:10.1093/cid/ciac279.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Bohnert ASB, O’Hare AM, et al. Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) Variant era. Ann Intern Med. 2022;175(12):1693–1706. doi:10.7326/M22-1856.
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Berry K, Rajeevan N, et al. Effectiveness of COVID-19 treatment with Nirmatrelvir-Ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. Ann Intern Med. 2023;176(6):807–816. www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-3565. eng. doi:10.7326/m22-3565.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023;23(7):806–815. doi:10.1016/s1473-3099(23)00118-4.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2022.
   Google Scholar
• National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2023.
   Google Scholar
• Food and Drug Administration. FDA updates sotrovimab emergency use authorization. 2022.
   Google Scholar
• Centers for Disease Control and Prevention. End of the federal COVID-19 public health emergency (PHE) declaration. 2023.
   Google Scholar
• Lin DY, Xu Y, Gu Y, et al. Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study. Lancet Infect Dis. 2023;23(11):1257–1265. doi:10.1016/s1473-3099(23)00272-4.
   PubMed Web of Science ®Google Scholar
• Bohnert AS, Kumbier K, Rowneki M, et al. Adverse outcomes of SARS-CoV-2 infection with Delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. BMJ. 2023;381:e074521. doi:10.1136/bmj-2022-074521.
   PubMedGoogle Scholar
• Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;381:e072705. doi:10.1136/bmj-2022-072705.
   Google Scholar
• Xie Y, Bowe B, Al-Aly Z. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;381:e073312. doi:10.1136/bmj-2022-073312.
   PubMedGoogle Scholar
• Lin D-Y, Xu Y, Gu Y, et al. Durability of bivalent boosters against Omicron subvariants. N Engl J Med. 2023;388(19):1818–1820. doi:10.1056/NEJMc2302462.
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising Conditions – VISION network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579–588. doi:10.15585/mmwr.mm7221a3.
   PubMedGoogle Scholar
• Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-Associated emergency department or urgent care encounters and hospitalizations among immunocompetent Adults – VISION network, nine states, September–November 2022. MMWR Morb Mortal Wkly Rep. 2023;71(53):1637–1646. doi:10.15585/mmwr.mm7153a1.
   PubMedGoogle Scholar
• Tseng H, Ackerson B, SyLS, et al. Effectiveness of mRNA-1273 bivalent (original and omicron BA.4/BA.5) COVID-19 vaccine in preventing hospitalizations for COVID-19, medically attended SARS-CoV-2 infections, and hospital death in the United States. medRxiv. 2023:2023.05.25.23290456. doi:10.1101/2023.05.25.23290456.
   Google Scholar
• Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of Post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554–564. doi:10.1001/jamainternmed.2023.0743.
   PubMed Web of Science ®Google Scholar
• Rathnayaka IW, Khanam R, Rahman MM. The economics of COVID-19: a systematic literature review. J Eco Stud. 2023;50(1):49–72. doi:10.1108/JES-05-2022-0257.
   Google Scholar
• Richards F, Kodjamanova P, Chen X, et al. Economic burden of COVID-19: a systematic review. Clinicoecon Outcomes Res. 2022;14:293–307. doi:10.2147/ceor.S338225.
   PubMed Web of Science ®Google Scholar
• Murton M, Drane E, Jarrett J, et al. Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review. Infection. 2023;51(2):285–303. doi:10.1007/s15010-022-01930-8.
   PubMed Web of Science ®Google Scholar